Anthony Gregg Lapointe - 23 May 2025 Form 4 Insider Report for RIGEL PHARMACEUTICALS INC (RIGL)

Reporting relationship: Director
Issuer ticker: RIGL
Reported as of: 23 May 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 28 May 2025, 17:27:06 UTC
Prior SEC filing: 13 Dec 2024
Next SEC filing: 12 Jun 2025
Source filing: View source filing
Reporting owner signature: /s/ Raymond Furey (Attorney-in-Fact)

Key filing fact

Anthony Gregg Lapointe filed Form 4 for RIGEL PHARMACEUTICALS INC (RIGL) on 28 May 2025.

Key facts

This page summarizes Anthony Gregg Lapointe's Form 4 filing for RIGEL PHARMACEUTICALS INC (RIGL).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 28 May 2025, 17:27.

Change

Previous filing in this sequence was filed on 13 Dec 2024.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001331860 Primary reporting owner

LAPOINTE ANTHONY GREGG

Relationship: Director
Address: C/O RIGEL PHARMACEUTICALS, INC., 611 GATEWAY BLVD, SUITE 900, SOUTH SAN FRANCISCO
Signature: /s/ Raymond Furey (Attorney-in-Fact)
Signature date: 28 May 2025

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

RIGL transaction

Common Stock

Award

Transaction value: $0
Shares: +2,500
Change %: +25%
Price: $0.000000
Shares after: 12,500
Date: 23 May 2025
Ownership: Direct
Footnotes: F1, F2

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

RIGL transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +3,000
Change %
Price: $0.000000
Shares after: 3,000
Date: 23 May 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 3,000
Exercise price: $18.95
Footnotes: F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

The shares of Common Stock are to be acquired upon the vesting of a Restricted Stock Unit award granted to the Reporting Person. The Restricted Stock Units shall fully vest on the date prior to the Company's next Annual Meeting, subject to the Reporting Person's continuous service on the Company's Board of Directors.

Footnote F2

This number has been adjusted to reflect the one-for-ten reverse stock split effective June 27, 2024.

Footnote F3

The shares vest monthly over one (1) year from the date of grant, subject to the Reporting Person's continuous service on the Company's Board of Directors.